Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 1.00 |
| ▸ | MITF | O75030 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.63 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12218027 | 1.00 | MAPT (1.00) | MAPTPOLBMITFMAPK1KMT2A | |
| SCHEMBL12639160 | 0.88 | MAPT (0.79) | MAPTPOLBMITFMAPK1KMT2A | |
| SCHEMBL1888911 | 0.87 | MAPT (0.77) | MAPTPOLBMITFMAPK1KMT2A | |
| SCHEMBL30828552 | 0.86 | KDM4E (0.85) | MAPTPOLBMITFMAPK1KMT2A | |
| SCHEMBL9134339 | 0.86 | KMT2A (0.83) | MAPTPOLBMITFMAPK1KMT2A | |
| SCHEMBL23999623 | 0.86 | KDM4E (0.85) | MAPTPOLBMITFMAPK1KMT2A | |
| SCHEMBL8572381 | 0.86 | KMT2A (0.83) | MAPTPOLBMITFMAPK1KMT2A | |
| SCHEMBL30828582 | 0.86 | KDM4E (0.85) | MAPTPOLBMITFMAPK1KMT2A | |
| SCHEMBL23898948 | 0.86 | KMT2A (0.83) | MAPTPOLBMITFMAPK1KMT2A | |
| SCHEMBL25822055 | 0.85 | MAPT (0.74) | MAPTPOLBMITFMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110256092-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110256092-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110256092-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7939546-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939546-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939546-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| CN-101889008-A | Be used to regulate the quinoline of dna methylation | SUPERGEN INC | 2010-11-17 | — | — | CN | disclosed |
| US-7790746-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790746-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790746-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090285772-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| CN-101535295-A | Quinoline derivatives for modulating DNA methylation | SUPERGEN INC (US) | 2009-09-16 | — | — | CN | disclosed |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009049132-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049132-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20080175814-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080175814-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080175814-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080175814-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | MAPT 3156/4885POLB 187/4885MITF 1794/4885 |
| US-20110256092-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | MAPT 3156/4885POLB 187/4885MITF 1794/4885 |
| US-20090285772-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | MAPT 3156/4885POLB 187/4885MITF 1794/4885 |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | MAPT 3156/4885POLB 187/4885MITF 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.